Comments
Aurobindo Pharma’s consolidated net profit decreased 22 per cent at ₹611 crore in the second quarter ended September 30, 2018 as compared to ₹781 crore in the corresponding quarter of the previous year.
The total revenue of the Hyderabad-based company increased by 7 per cent at ₹4,751 crore as against ₹4,436 crore.
Terming the company’s performance as ‘healthy’, its Managing Director N. Govindarajan, Managing Director, said, “Our focused efforts to commercialise differentiated product baskets are aimed at creating sustainable profitability for the future.’’ The company filed two Abbreviated New Drug Applications (ANDAs) in dermatology and one nasal ANDA in the first half of the fiscal.
The board had approved an interim divided at 125 pc, i.e., ₹1.25 per equity share of ₹1 for the financial year 2018-19.
Comments
COMMENT NOW
Comments
Comments have to be in English, and in full sentences. They cannot be abusive or personal. Please abide by our community guidelines for posting your comments.
We have migrated to a new commenting platform. If you are already a registered user of TheHindu Businessline and logged in, you may continue to engage with our articles. If you do not have an account please register and login to post comments. Users can access their older comments by logging into their accounts on Vuukle.